Edgewise Therapeutics’ EDG-7500 Emerges as New HCM Contender
CardiacWire
SEPTEMBER 22, 2024
A new HCM competitor emerged last week, after Edgewise Therapeutics’ EDG-7500 showed strong evidence of its safety and efficacy in a pair of early-stage trials. EDG-7500 is an oral cardiac sarcomere modulator designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diastolic dysfunctions. EDG-7500 is later to the HCM party than BMS’ Camzyos and Cytokinetics’ aficamten, but is differentiated by its potential to improve blood flow without sa
Let's personalize your content